HC Wainwright set a $36.00 price objective on XOMA (NASDAQ:XOMA) in a report issued on Wednesday morning. The firm currently has a buy rating on the biotechnology company’s stock.

XOMA has been the subject of a number of other research reports. Wedbush reiterated an outperform rating on shares of XOMA in a research note on Monday, September 17th. Zacks Investment Research downgraded shares of XOMA from a buy rating to a hold rating in a research note on Saturday, July 21st. S&P Equity Research lowered their target price on shares of XOMA from $18.74 to $16.26 in a research note on Tuesday, August 14th. Finally, ValuEngine downgraded shares of XOMA from a hold rating to a sell rating in a research note on Friday, September 7th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of $28.07.

Shares of NASDAQ:XOMA traded down $0.37 during trading on Wednesday, hitting $14.39. The company’s stock had a trading volume of 88,924 shares, compared to its average volume of 105,124. The company has a quick ratio of 12.46, a current ratio of 12.46 and a debt-to-equity ratio of 3.06. The company has a market cap of $116.41 million, a price-to-earnings ratio of 14.68 and a beta of 2.75. XOMA has a fifty-two week low of $11.88 and a fifty-two week high of $37.25.

XOMA (NASDAQ:XOMA) last issued its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.40). The firm had revenue of $0.90 million for the quarter, compared to analyst estimates of $0.83 million. XOMA had a negative return on equity of 214.93% and a negative net margin of 129.85%. On average, analysts expect that XOMA will post -1.14 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. lifted its position in XOMA by 0.8% in the third quarter. BlackRock Inc. now owns 452,542 shares of the biotechnology company’s stock valued at $7,951,000 after acquiring an additional 3,686 shares during the last quarter. Bank of New York Mellon Corp lifted its position in XOMA by 41.8% in the third quarter. Bank of New York Mellon Corp now owns 50,560 shares of the biotechnology company’s stock valued at $888,000 after acquiring an additional 14,899 shares during the last quarter. Acadian Asset Management LLC lifted its position in XOMA by 6.0% in the third quarter. Acadian Asset Management LLC now owns 101,820 shares of the biotechnology company’s stock valued at $1,789,000 after acquiring an additional 5,769 shares during the last quarter. Northern Trust Corp lifted its position in XOMA by 308.6% in the second quarter. Northern Trust Corp now owns 68,200 shares of the biotechnology company’s stock valued at $1,424,000 after acquiring an additional 51,510 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd lifted its position in XOMA by 57.6% in the second quarter. Dynamic Technology Lab Private Ltd now owns 20,112 shares of the biotechnology company’s stock valued at $420,000 after acquiring an additional 7,349 shares during the last quarter. 43.49% of the stock is owned by hedge funds and other institutional investors.

About XOMA

XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.

Recommended Story: Moving Average – How it Helps Investors in Stock Selection

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.